The purpose of this study is to test the safety and tolerability of an investigational
inhaled flu medication, CS-8958. Study participants will include 38 elderly males and
females, age 65 and older. Participants will be divided into 1 of 4 possible treatment groups
(Groups A, B, C and D) to receive the study drug or placebo (substance containing no
medication). Group A will receive 5 mg CS-8958, Group B will receive 10 mg CS-8958, Group C
will receive 20 mg CS-8958 and Group D will receive 40mg CS-8958. Safety information will be
reviewed prior to administering a higher dose of treatment. Study procedures will include
blood and urine samples, ECGs (measure of heart activity), and a 7 day clinic stay.
Participants will be involved in study related procedures for up to 6 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Biota Scientific Management Pty Ltd
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)